Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388937 | 1.00 | HRH3 (0.70) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL9216464 | 1.00 | HRH3 (0.70) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL5397114 | 1.00 | HRH3 (0.70) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL3389073 | 1.00 | HRH3 (0.70) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL5397440 | 1.00 | HRH3 (0.70) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL6715590 | 0.97 | HRH3 (0.75) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL5395587 | 0.97 | HRH3 (0.75) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL10709367 | 0.97 | HRH3 (0.75) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL11460076 | 0.97 | HRH3 (0.75) | HRH3MAPTSIGMAR1CXCR4CYP1A2 | |
| SCHEMBL5385522 | 0.97 | HRH3 (0.75) | HRH3MAPTSIGMAR1CXCR4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | HRH3 1919/4885MAPT 4237/4885SIGMAR1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.